Keywords: cat-192, safe, efficacy, doubt, uk-headquartered, cambridge, antibody

CAT-192 is safe but efficacy in doubt

Article | 16 February 2004

Print This

UK-headquartered Cambridge Antibody Technology and the USA's Genzyme Corp have revealed that Phase I/II trials of CAT-192 for scleroderma ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in